凯发k8一触即发

EN|News Releases

News Releases

Media

Home>Media
China Resources Zizhu Forges Strategic Alliance with Uni-Bio Science Group

Press time:2016-06-27From:CR Zizhu [ Font:BigMediumSmall]

(27 June 2016, Hong Kong) –China Resources Zizhu Pharmaceutical Co., Limited (“CR Zizhu”), a wholly owned subsidiary of CR Pharma, has today announced that it has signed a strategic alliance agreement with Uni-Bio Science Group Limited (“Uni-Bio Science”, HKEx code:690). The agreement is relate to the sole distribution and promotion rights of GeneSoft in China.

Under the partnership, GeneSoft has immediate access to CR Zizhu’s network for commercializing the drug, a distribution platform with a proven track record and seasoned sales and marketing team. Its believes that through leveraging CR Zizhu’s extensive distribution network and expertise in sales and marketing, distribution of GeneSoft can be expanded to new regions more quickly, thereby driving further business growth. On the other hand, CR Zizhu can also enriched its ophthalmologic product line and able to speed up establishing presence in the ophthalmology market. The two parties therefore reach a win-win situation.

GeneSoft is an ophthalmic solution containing a derivative of recombinant human epidermal growth factor (rhEGF) which enhances the healing of cornea wounds by promoting corneal epithelium regeneration. The mechanism of action is unique and therefore highly applicable to a wide range of ophthalmology indications, including dry eyes, and trauma after ocular surgery (e.g. LASIKI).

Listed on the Hong Kong Stock Exchange in 2001, Uni-Bio Science is a leading Chinese biopharmaceutical company engaged in the research, development, production and commercialization of biopharmaceuticals for the Chinese healthcare market.

CR Zizhu, a wholly owned subsidiary of China Resources Pharmaceutical Group, is a leader in the reproductive health pharmaceutical market in China and has achieved rapid development in the R&D and marketing of ophthalmologic drugs. In recent years, CR Zizhu has actively expanded in the ophthalmologic treatment segment.

Mr.Wu Jun, Senior Deputy General Manager of CR Pharma and Chairman of CR Zizhu (first row, right) and Mr.KOH Phee Wah, CEO of China Operations of Uni-Bio Science (first row, left) attend the signing ceremony.

 

Prev | Next
Back to Top